Physician profile
Gregory M Francisco
NPI 1447222831
$27,451.39
in general payments reported to CMS, 2019-2025
17 companies · $2,946 in 2025
The $2,946 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $408 · 2021: $860 · 2022: $553 · 2023: $11K · 2024: $11K · 2025: $2,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $4,647 · Travel and Lodging: $3,789 · Education: $27.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,500.00 |
| Food and Beverage | $4,647.15 |
| Travel and Lodging | $3,789.26 |
| Education | $27.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $17,076.88 | 2023-2025 | Carto 3 |
| Abbott Laboratories | $5,150.24 | 2019-2025 | Aveir, Ensite, Amplatzer Talisman |
| Medtronic, INC. | $1,467.89 | 2021-2023 | Micra, Corevalve Evolut R, Azure Xt Dr Mri Surescan |
| Biosense Webster, INC. | $1,294.57 | 2019-2025 | Carto 3, Octaray Mapping Catheter, Qdot Micro Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $758.46 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $595.74 | 2019-2025 | Watchman Flx, Farapulse, General - Therapies |
| Biotronik INC. | $328.89 | 2019-2020 | |
| Edwards Lifesciences Corporation | $223.58 | 2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $146.03 | 2024 | Xarelto |
| Abiomed | $136.58 | 2025 | |
| Terumo Medical Corporation | $68.74 | 2019-2022 | |
| Medtronic Vascular, INC. | $47.99 | 2020 | |
| Chiesi USA, INC. | $47.33 | 2022-2025 | Kengreal |
| Kiniksa Pharmaceuticals, LTD. | $37.72 | 2022-2023 | Arcalyst |
| Amgen INC. | $37.20 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16.91 | 2019 | |
| Philips North America LLC | $16.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Francisco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.